First-Line Antiretroviral Therapy With a Protease Inhibitor Versus Non-Nucleoside Reverse Transcriptase Inhibitor and Switch at Higher Versus Low Viral Load in HIV-infected Children: An Open-Label, Randomised Phase 2/3 Trial
The Lancet Infectious Diseases - United Kingdom
doi 10.1016/s1473-3099(10)70313-3
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 1, 2011
Authors
Unknown
Publisher
Elsevier BV